[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity

Rhea-AI Filing Summary

Ryan Savitz, Chief Financial Officer and Chief Business Officer of Dianthus Therapeutics, Inc. (DNTH), was granted a stock option on September 23, 2025 to purchase 60,000 shares of common stock at an exercise price of $37.87 per share. The option vests in equal monthly installments over four years beginning on the grant date and expires on September 23, 2035. The reporting on Form 4 was signed by an attorney-in-fact on September 25, 2025. The award is reported as a direct beneficial ownership of 60,000 underlying shares immediately following the transaction.

Positive

• Aligns management incentives by tying compensation to future share-price performance through time-based vesting
• Retention-focused structure with monthly vesting over four years encourages continued service
• Transparent disclosure filed on Form 4 with exercise price, vesting, and expiration clearly stated

Negative

• Potential dilution from 60,000 underlying shares if exercised (materiality depends on total shares outstanding)
• Execution price of $37.87 may be above or below current market price (market-relative impact not stated in filing)

Insights

Corporate Compensation Analyst

TL;DR: Standard time-based option grant to a senior executive to align incentives and retain key management.

The award of 60,000 stock options at a $37.87 exercise price appears to be a routine, time-based equity grant for an executive officer. Vesting monthly over four years is a common retention structure that ties potential upside to continued service and future share-price performance. For investors, this indicates management alignment with shareholder value creation but does not itself provide new operating information about the business. The grant size should be evaluated relative to total shares outstanding and company equity-compensation practices to assess dilution and cost.

Securities Governance Specialist

TL;DR: Disclosure meets Section 16 requirements; no red flags in the filing mechanics or timing.

The Form 4 properly discloses the option grant, exercise price, vesting schedule, and expiration date, and it is timely executed by an attorney-in-fact. There is no indication of accelerated vesting, related-party anomalies, or atypical transaction codes. From a governance perspective, this is a transparent reporting of insider compensation and complies with required reportage standards.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Savitz Ryan

(Last) (First) (Middle)

C/O DIANTHUS THERAPEUTICS, INC.

7 TIMES SQUARE, 43RD FLOOR

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Dianthus Therapeutics, Inc. /DE/ [ DNTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & CBO

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$37.87	09/23/2025		A		60,000		(1)	09/23/2035	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. The shares of common stock underlying this stock option award will vest in equal monthly installments over the four years after September 23, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Adam Veness, as attorney-in-fact for Ryan Savitz	09/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did DNTH insider Ryan Savitz report on Form 4?

The filing reports a grant of 60,000 stock options to Ryan Savitz on September 23, 2025 with an exercise price of $37.87 and an expiration date of September 23, 2035.

How do the options awarded to Ryan Savitz vest?

The options vest in equal monthly installments over four years beginning from the grant date, subject to continued service.

Does the Form 4 show how many shares Savitz owns after the grant?

The Form 4 reports 60,000 underlying shares as beneficially owned following the reported transaction.

Was the Form 4 filing for DNTH timely and properly signed?

Yes. The Form 4 was signed by an attorney-in-fact on behalf of Ryan Savitz on September 25, 2025.

What is the exercise price and expiration for the options?

The options have an exercise price of $37.87 and an expiration date of September 23, 2035.